ABCG2 was originally cloned from breast tumor cell lines and placental tissue in 1998 [158,159,160] and its isolation from a multidrug resistant breast cancer (Mcf7-derived) cell line led to its latest term as the ‘breast cancer resistance protein.’ MDR is the most frequent phenomenon associated with the failure of chemotherapy. Here, ABCG2 is linked to breast cancer.